Teva的切片病新药 获得了FDA快车道状态 加快了审查过程 Teva's new drug for celiac disease gets FDA Fast Track status, speeding up review process.

Teva Pharmaceutical Industries 的新药 TEV-53408 已获得 FDA 的快速通道指定，该药物旨在治疗无麸质饮食的成人乳糜泻。 Teva Pharmaceutical Industries has received Fast Track designation from the FDA for its new drug, TEV-53408, designed to treat celiac disease in adults on a gluten-free diet. 该药物目前处于第2a阶段试验阶段,旨在抑制内肠道介质-15,减少大肠杆菌患者的肠道损伤。 The drug, currently in Phase 2a trials, aims to inhibit interleukin-15, reducing intestinal damage in celiac patients. " 快车道 " 状态加快了针对严重病情的药物的审查进程。 Fast Track status accelerates the review process for drugs addressing serious conditions. Celiac疾病影响全球人口的约1%。 Celiac disease affects about 1% of the global population.